WeTrials
Completed

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 TRIAL)

What is this study?

This study is testing an experimental medication called tavapadon to see if it safely and effectively helps manage early symptoms of Parkinson's disease, such as stiffness and shaking. By comparing tavapadon against a placebo, researchers can better understand its benefits for patients.

Who can participate?

Adults between 40 and 80 years old with an early-stage Parkinson's disease diagnosis who meet specific health guidelines can join. Participants must also agree to follow all study rules and use reliable birth control if they can have children.

What will happen?

Participants will take either tavapadon or an inactive placebo for 27 weeks to test the safety and effectiveness of the study medication. Regular check-ins will monitor your health and how well you tolerate the treatment throughout the study.

Where and when?

This study has multiple locations across the United States, including sites in Alabama, Arkansas, and California. The study is currently completed and has finished gathering its research data.

Key Points
  • 1Testing tavapadon for early Parkinson's disease symptoms
  • 2Compares the study drug against an inactive placebo
  • 3Lasts for 27 weeks with multiple U.S. locations

Related video

NeurologyLive: TEMPO trials lead investigator on how tavapadon works (May 2026)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Parkinson Disease

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.